BARDA Funds Our OMICs Research Across NB-UVB Trials for MS, COVID, and HTN

December 9, 2022

We are excited to announce that BARDA is partnering with Cytokind’s team to expand its clinical trial to further validate a phototherapy device. Our grant award is the first non-pharmacological therapeutic to be given in an effort to support BARDA’s Division of Research, Innovation, and Ventures (DRIVe). The awards announced are part of BARDA DRIVe’s medical countermeasure portfolio.

medicalcountermeasures.gov/newsroom/2022/covidtreatments/